Last reviewed · How we verify
Cook County Health — Portfolio Competitive Intelligence Brief
5 marketed
0 filed
0 Phase 3
0 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| NPH insulin and regular insulin | NPH insulin and regular insulin | marketed | ||||
| Glipizide XL | Glipizide XL | marketed | ||||
| Non-medicated patch | Non-medicated patch | marketed | ||||
| Glipizide and Glargine | Glipizide and Glargine | marketed | Insulin secretagogue + Long-acting insulin | ATP-sensitive potassium channel (glipizide); Insulin receptor (glargine) | Diabetes | |
| Warfarin and Enoxaparin | Warfarin and Enoxaparin | marketed | Anticoagulant combination (vitamin K antagonist + low-molecular-weight heparin) | Vitamin K-dependent clotting factors (warfarin); Factor Xa and Factor IIa (enoxaparin) | Cardiovascular |
Therapeutic area mix
- Cardiovascular · 1
- Diabetes · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Cook County Health:
- Cook County Health pipeline updates — RSS
- Cook County Health pipeline updates — Atom
- Cook County Health pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Cook County Health — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cook-county-health. Accessed 2026-05-16.